


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of the formula Z:



where;

A is CH or N;

R₁ is a substituent to a carbon atom in the ring containing A selected from

-S(=O)_pR_a,

where R_a is -C₁-C₄ alkyl, -OR_x, -NR_xR_x, -NHNR_xR_x, -

NHNHC(=O)OR_x, -NR_xOH;

-C(=O)-R_b,

where R_b is -C₁-C₄-alkyl, OR_x, -NR_xR_x, -NHNR_xR_x,

-NHC₁-C₃-alkyl-C(=O)OR_x;

-NR_xR_c,

where R_c is H, C₁-C₄ alkyl, -NR_xR_x; -C(=O)R_d, -CN, S(=O)_pR_x

where R_d is R_d is C₁-C₄-alkyl, -OR_x, -NR_xR_x

-C₁-C₃-alkyl-O-C₁-C₃alkylC(=O)OR_x[],[];

-C₁-C₃-alkyl-COOR_x;

-C₁-C₃alkyl-OR_x;

-(O-C₁-C₃alkyl)_q-O-R_x;

a 5 or 6 membered aromatic ring have 1-3 hetero atoms;

p and q are independently selected from 1 or 2;

R_x is independently selected from H, C₁-C₄ alkyl or acetyl; or a pair of R_x can together with the adjacent N atom form a pyrrolidine, piperidine, piperazine or morpholine ring;

R₂ is a substituent to a carbon atom in the ring containing A and is H, halo, cyano, C₁-C₄-alkyl, haloC₁-C₄-alkyl;

L is -O-, -S(=O)_r- or -CH₂-_r, where r is 0, 1 or 2;

R₃ is H, C₁-C₃ alkyl;

R₄-R₇ are independently selected from H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, haloC₁-C₆ alkyl, C₁-C₆ alkanoyl, haloC₁-C₆ alkanoyl, C₁-C₆ alkoxy, haloC₁-C₆ alkoxy, C₁-C₆ alkyloxyC₁-C₆ alkyl, haloC₁-C₆ alkyloxyC₁-C₆ alkyl, hydroxyC₁-C₆ alkyl, aminoC₁-C₆ alkyl, carboxyC₁-C₆ alkyl, cyanoC₁-C₆ alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto;

X is -(CR₈R₈')_n-D-(CR₈R₈')_m-;

T is O or S;

D is a bond, -NR₉-, -O-, -S-, -S(=O)- or -S(=O)₂-;

n and m are independently 0, 1 or 2, provided that they are not both 0 when D is a bond;

R₈ and R₈' are independently H, C₁-C₃ alkyl, haloC₁-C₃alkyl, hydroxy, or R₈ and R₈' together with their adjacent C atom is -C(=O)-

R₉ is independently H, C₁-C₃ alkyl;


and pharmaceutically acceptable salts and prodrugs thereof;

with the proviso that R₁ as -C(=O)Rb is not morpholinoketo-.

2. (Original) A compound according to claim 1, wherein T is O.

3. (Original) A compound according to claim 1, wherein R₃ is H.

4. (Currently Amended) A compound according to claim 1, wherein the cyclopropyl moiety has an enantiomeric excess of the conformation depicted in the partial formulae:



where X is as defined, Y is the bridge-bond to the (substituted) phenyl ring depicted in formula I and Z is the bond to the (thio)urea-pyridyl moiety depicted in formula Z.

5. (Original) A compound according to claim 1 wherein the compound of formula Z comprises an enantiomeric excess of the isomer showing negative optical activity.

6. (Original) A compound according to claim 1, wherein D is -O-

7. (Original) A compound according to claim 6, wherein n is 0 and m is 1.

8. (Original) A compound according to claim 1, wherein R₄ is hydrogen, fluoro or hydroxy.

9. (Original) A compound according to claim 1, wherein R₅ is hydrogen, fluoro, C₁₋₃ alkylcarbonyl or C₁₋₃alkyloxy.

10. (Original) A compound according to claim 1, wherein R₆ is hydrogen, halo, C₁₋₃alkyloxy, C₁₋₃alkylcarbonyl, cyano or ethynyl.

11. (Original) A compound according to claim 10, wherein R6 is hydrogen, methoxy or fluoro.

12. (Original) A compound according to claim 1, wherein R7 is hydrogen, cyano, halo, C1-3alkyloxy, or C1-3alkylcarbonyl.

13. (Original) A compound according to claim 12, wherein R7 is cyano, fluoro or acetyl.

14. (Original) A compound according to claim 1, wherein R5 and R6 are H and R4 and R7 are fluoro.

15. (Original) A compound according to claim 1, wherein R4 is fluoro, R5 and R6 are H, and R7 is cyano or acetyl.

16. (Original) A compound according to claim 1, wherein L is $-O-$.

17. (Original) A compound according to claim 1, wherein R1 is $-S(=O)2NRxRx$, $S(=O)2C1-C4$ alkyl, or $S(=O)C1-C4$ alkyl.

18. (Original) A compound according to claim 17, wherein R1 is $-S(=O)2NH2$, $-S(=O)2NMe2$ or $-S(=O)2NH$ -cyclopropyl.

19. (Original) A compound according to claim 17, wherein R1 is $-S(=O)2Me$ or $-S(=O)Me$.

20. (Original) A compound according to claim 1, wherein R1 is $-C(=O)OR_x$, $-C(=O)NR_xR_x$, $-C(=O)NHNR_xR_x$ or $-C(=O)NHCH_2COOR_x$.

21. (Original) A compound according to claim 20, wherein R1 is $-C(=O)OH$, $-C(=O)OMe$, $-C(=O)NH_2$, $-C(=O)NHMe$, $-C(=O)NHNH_2$, $-C(=O)NHCH_2COOH$.

22. (Original) A compound according to claim 20, wherein R1 is $-C(=O)NR_x'-N$ -morpholine, $-C(=O)NR_x'-N$ -piperidine, $-C(=O)NR_x'-N$ -pyrrolidine or $-C(=O)NR_x'-N$ -piperazine, where Rx is methyl, acetyl or preferably H.

23. (Original) A compound according to claim 1, wherein R1 is $-NR_xR_x$, $-N(C=O)C_1-C_4$ -alkyl or $-NHC(=O)CH_2OC_1-C_3$ -alkyl-COORx.

24. (Original) A compound according to claim 23, wherein R1 is $-NH_2$, $-NHC(=O)Me$ or $NHC(=O)CH_2OCH_2C(=O)OH$.

25. (Original) A compound according to claim 1, wherein R1 is $-C_1-C_3$ -alkyl-COORx; $-C_1-C_3$ alkyl-ORx, $-(O-C_1-C_3$ alkyl)q-O-Rx or a 5 membered ring having 1-3 hetero atoms.

26. (Original) A compound according to claim 25, wherein R1 is carboxyethyl or a methyl ester thereof, 2-methoxyethoxyethoxy or triazolyl.

27. (Original) A compound according to claim 1, wherein R1 is para to the ether linkage.

28. (Original) A compound according to claim 1, wherein the ring containing A is phenyl or pyrid-3-yl.

29. (Original) A compound according to claim 1, wherein R2 is hydrogen or fluoro.

30. (Original) A compound according to claim 1 where R2 is meta to the ether linkage.

31. (Original) A compound according to claim 1 denoted N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-(5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea

32. (Original) A pharmaceutical composition comprising a compound as defined in any preceding claim and a pharmaceutically acceptable vehicle or diluent therefor.

33. (Original) A composition according to claim 32, further comprising 1 to 3 additional HIV antivirals.


34. (Original) A composition according to claim 32, further comprising a cytochrome P450 modulator, such as ritonavir.

35. **(Previously Presented)** A method for the prophylaxis or treatment of HIV-1 infections comprising administering to an individual in need thereof an effective amount of the compound according to claim 1.

36. **(Previously Presented)** The method according to claim 35, wherein the HIV-1 infection is a drug escape mutant.

37. **(Previously Presented)** The method according to claim 36, wherein the drug escape mutant comprises the L100I and K103N mutations.

38. **(NEW)** The method according to claim 35, wherein said compound is N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-(5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea



39. **(NEW)** The method according to claim 35, wherein the administration is vaginal.